



# PRELIMINARY SCIENTIFIC PROGRAMME

## OPENING CEREMONY and PLENARY LECTURE

PL01	The year in the thyroid E. Chester Ridgway (USA)	Saturday 11 Sept. 06:30 pm - 07:30 pm
------	---	--

## PLENARY LECTURES

PL02	Special Plenary Lecture	Sunday 12 Sept. 08:30 am - 09:20 am
PL03	ETA Prize Lecture	Monday 13 Sept. 08:30 am - 09:20 am
PL04	LATS Prize Lecture	Tuesday 14 Sept. 08:30 am - 09:20 am
PL05	ATA Van Meter Award Lecture	Wednesday 15 Sept. 08:30 am - 09:20 am
PL06	AOTA Prize Lecture	Thursday 16 Sept. 08:30 am - 09:20 am

## DEBATES

DB01	<b>DO NOT TREAT SUBCLINICAL HYPOTHYROIDISM</b> Jean-Louis Wemeau (France) the "PRO" point of view. Mario Vaisman (Brazil) the "CON" point of view.	Tuesday 14 Sept. 11:30 am - 12:10 am
DB02	<b>THYROID STEM CELLS DO NOT EXIST</b> Terry Davies (USA) the "PRO" point of view. Jacques Dumont (Belgium) the "CON" point of view.	Tuesday 14 Sept. 12:20 am - 01:00 pm

## IMPLEMENTING GUIDELINES

IG01	<b>IMPLEMENTING GUIDELINES FOR DIFFERENTIATED THYROID CANCER</b> Furio Pacini (Italy), David Cooper (USA), Yasuhiro Ito (Japan), Nelson Wohlk (Chile)	Sunday 12 Sept. 11:30 am - 01:00 pm
IG02	<b>IMPLEMENTING GUIDELINES FOR THYROID NODULES</b> Ralf Paschke (Germany), Susan Mandel (USA) Hirotoshi Nakamura (Japan), Fabian Pitoia (Argentina)	Monday 13 Sept. 11:30 am - 01:00 pm
IG03	<b>IMPLEMENTING GUIDELINES FOR MEDULLARY THYROID CANCER</b> Richard Kloos (USA), Henning Dralle (Germany) Ana Luisa Maia (Brazil), Akira Miyauchi (Japan)	Wednesday 15 Sept. 11:30 am - 01:00 pm

## MEET THE EXPERTS\*

(\* ) 6 sessions will run in parallel each day

ME01	Treatment of paediatric Graves' disease <b>Scott Rivkees</b> (USA)
ME02	Thyroid and male gonad <b>Gerasimos Krassas</b> (Greece)
ME03	Clinical implications of anti-TSH receptor antibodies <b>Keiichi Kamijo</b> (Japan)
ME04	Thyrotoxic periodic paralysis <b>Annie C. Kung</b> (China)
ME05	Enigma in the low T3- syndrome (debate) Deiodinase 1 vs Deiodinase 3 <b>Ronald J. Koenig</b> (USA), <b>Anita Boelen</b> (The Netherlands)
ME06	"Omics" in thyroid cancer research <b>Barbara Jarzab</b> (Poland)
ME07	Management of postpartum thyroiditis <b>Nobuyuki Amino</b> (Japan)
ME08	Targets of T4 treatment in hypothyroidism <b>Maria Alevizaki</b> (Greece)
ME09	Immuno-modulators of thyroid functions <b>Luca Chiovato</b> (Italy)
ME10	Radiation and the thyroid gland <b>Shigenobu Nagataki</b> (Japan)
ME11	Imprinting epigenetic regulation of the deiodinase 3 gene <b>Arturo Hernandez</b> (USA)
ME12	New signalling pathways in the thyrocyte <b>Ana Maria Masini-Repiso</b> (Argentina)
ME13	Subclinical hyperthyroidism <b>José Augusto Sgarbi</b> (Brazil)
ME14	The management of thyroid eye disease <b>Anja Eckstein</b> (Germany), <b>Petros Perros</b> (UK)
ME15	Management of paediatric medullary thyroid carcinoma <b>Steven Waguespack</b> (USA)
ME16	A new sensitive thyroglobulin assay <b>Rui Maciel</b> (Brazil)
ME17	Cathepsin-mediated thyroglobulin proteolysis and thyroid hormone release <b>Klaudia Brix</b> (Germany)
ME18	Control of cerebellar development by thyroid hormones <b>Frédéric Flamant</b> (France)
ME19	The risks of 131I <b>Florent de Vathaire</b> (France)
ME20	Neck-imaging: which nodule should be biopsied? <b>Eun Kyung Kim</b> (Korea)
ME21	Iodine in pregnancy <b>Sumihisa Kubota</b> (Japan)

## Sunday 12 Sept.

1:15 pm - 1:55 pm

## Monday 13 Sept.

1:15 pm - 1:55 pm

## Tuesday 14 Sept.

1:15 pm - 1:55 pm

## Wednesday 15 Sept.

1:15 pm - 1:55 pm



ME22	Screening for congenital hypothyroidism <b>Lea Maciel</b> (Brazil)
ME23	Cross-talks among signalling pathways in thyroid cancer cells <b>Minho Shong</b> (Korea)
ME24	Disruptors of thyroid hormone actions <b>Noriyuki Koibuchi</b> (Japan)

## SYMPOSIA

SY01	<b>THYROID IN THE FACE OF CHANGING IODINE INTAKE</b> The changing epidemiology of iodine deficiency <b>Mu Li</b> (Australia) Worldwide changes in iodine intake <b>Eduardo Pretell</b> (Peru) Novel strategies for control of iodine deficiency <b>Michael Zimmermann</b> (Switzerland) Consequences of changes in iodine intake for the occurrence of thyroid disorders <b>Peter Laurberg</b> (Denmark)	<b>Sunday 12 Sept.</b> 11:30 am - 01:00 pm
SY02	<b>THE TSH RECEPTOR AND AUTO-IMMUNE THYROID DISEASE</b> Polymorphisms in the TSH receptor <b>Stephen C.L. Gough</b> (UK) Model of TSH receptor activation by ligands and autoantibodies <b>Gilbert Vassart</b> (Belgium) Mechanisms of cleavage and shedding of a soluble form of the TSH receptor <b>Gunnar Kleinau</b> (Germany) Animal models of Graves' disease <b>Yuji Nagayama</b> (Japan)	<b>Sunday 12 Sept.</b> 11:30 am - 01:00 pm
SY03	<b>NEW INSIGHTS INTO THE CONTROL OF THYROID HORMONE ACTION</b> Entry & exit of thyroid hormone into/from tissues <b>Theo Visser</b> (The Netherlands) Intracellular thyroid hormone activation and inactivation by deiodinases <b>Domenico Salvatore</b> (Italy) Molecular models of ligand-TR interactions <b>Paul Webb</b> (USA) Co-activators and co-repressors for regulating thyroid hormone receptors <b>Fred Wondisford</b> (USA)	<b>Sunday 12 Sept.</b> 11:30 am - 01:00 pm
SY04	<b>THYROID NODULES</b> Elastography in the diagnosis of thyroid nodules <b>Paolo Vitti</b> (Italy) Molecular diagnosis of thyroid nodules <b>Yuri Nikiforov</b> (USA)	<b>Sunday 12 Sept.</b> 4:45 pm - 6:15 pm

	<p>Can drugs shrink thyroid nodules? <b>Martin Grussendorf</b> (Germany)</p> <p>Treatment of Multinodular goiter by rhTSH-stimulated 131I ablation <b>Hans Graf</b> (Brazil)</p>	
<b>SY05</b>	<p><b>NUCLEAR ACCIDENTS AND THYROID BLOCKADE: ARE WE READY?</b> (<i>Sponsored by Electricité de France</i>)</p> <p>Chernobyl consequences: Thyroid dysfunction and cancer <b>Michael Tuttle</b> (USA)</p> <p>Are there health consequences in the vicinity of nuclear power plants in normal functioning conditions ? <b>Jacques Esteve</b> (France)</p> <p>Iodine thyroid blocking in nuclear and radiological emergencies <b>Shunichi Yamashita</b> (Japan)</p> <p>The predistribution of potassium iodine tablets : the French experience <b>Yves Garcier</b> (France)</p>	<p><b>Sunday 12 Sept.</b> 4:45 pm - 6:15 pm</p>
<b>SY06</b>	<p><b>ALLAN-HERNDON-DUDLEY SYNDROME AND THYROID HORMONE TRANSPORTERS</b></p> <p>Genetics of plasma membrane transporters. <b>Edith Friesema</b> (The Netherlands)</p> <p>Early attempts in the treatment of MCT8 gene defects <b>Samuel Refetoff</b> (USA)</p> <p>Molecular basis for differences in human and mouse brain phenotypes <b>Ulrich Schweizer</b> (Germany)</p> <p>Thyroid hormone transporters in the brain <b>Grant Anderson</b> (USA)</p>	<p><b>Sunday 12 Sept.</b> 4:45 pm - 6:15 pm</p>
<b>SY07</b>	<p><b>NON-MAMMALIAN MODELS IN THYROID RESEARCH</b></p> <p>The Zebrafish <b>Robert Opitz</b> (Belgium)</p> <p>Birds (Quail) <b>Takashi Yoshimura</b> (Japan)</p> <p>Chicken <b>Veerle Darras</b> (Belgium)</p> <p>Amphibia <b>Yun-Bo Shi</b> (USA)</p>	<p><b>Sunday 12 Sept.</b> 4:45 pm - 6:15 pm</p>
<b>SY08</b>	<p><b>SELENIUM AND THE THYROID</b></p> <p>Selenium intake and thyroid hormone physiology <b>Lutz Schomburg</b> (Germany)</p> <p>Selenium and thyroid autoantibodies <b>Silvia Eskes</b> (The Netherlands)</p> <p>Selenium in mild Graves' Orbitopathy <b>Claudio Marcocci</b> (Italy)</p> <p>Maternal selenium status, thyroid function, and pregnancy outcome <b>Victor Pop</b> (The Netherlands)</p>	<p><b>Monday 13 Sept.</b> 11:30 am - 01:00 pm</p>
<b>SY09</b>	<p><b>MOLECULAR MECHANISMS OF THYROID CANCER – BASIC</b></p> <p>Micro-RNA <b>Edna Teruko Kimura</b> (Brazil)</p> <p>Tumor immunology and associated macrophages <b>James Fagin</b> (USA)</p> <p>Thyroid cancer stem cells <b>Norisato Mitsutake</b> (Japan)</p>	<p><b>Monday 13 Sept.</b> 11:30 am - 01:00 pm</p>



<b>SY10</b>	<b>HYPOTHALAMIC CONTROL OF ENERGY HOMEOSTASIS</b> Thyroid hormone signalling and metabolic control <b>Anthony Hollenberg (USA)</b> Modulation of hepatic glucose production by central thyroid hormone action <b>Lars Klieverik (The Netherlands)</b> The role of the thyrotropin-releasing hormone (TRH) neuron as a metabolic sensor in health and disease <b>Csaba Fekete (Hungary)</b> Leptin signalling in the hypothalamo-pituitary-thyroid axis <b>Egberto G Moura (Brazil)</b>	<b>Monday 13 Sept.</b> 11:30 am - 01:00 pm
<b>SY11</b>	<b>MECHANISM-BASED THERAPEUTICS FOR ADVANCED THYROID CANCERS</b> Overview of therapeutic targets <b>Massimo Santoro (Italy)</b> Selection of patients for targeted therapies <b>Lars Bastholt (Denmark)</b> Results of clinical trials of targeted therapies <b>Dave Pfister (USA)</b> Management of off-target toxicity <b>Manisha Shah (USA)</b>	<b>Monday 13 Sept.</b> 4:45 pm - 6:15 pm
<b>SY12</b>	<b>MANAGEMENT OF GRAVES' OPTHALMOPATHY (GO)</b> Immunopathogenesis of GO: Where do we stand? <b>Rebecca Bahn (USA)</b> Ethnic differences in the clinical presentation of GO <b>Daphne Khoo (Singapore)</b> Optimal use of steroids in GO and the role of high dose IV methyl-prednisolone <b>Luigi Bartalena (Italy)</b> Novel treatments of GO <b>Mario Salvi (Italy)</b>	<b>Monday 13 Sept.</b> 4:45 pm - 6:15 pm
<b>SY13</b>	<b>TRANSPORTERS IN THYROID CELL BIOLOGY</b> Structure-function relationship of the sodium/iodide symporter (NIS) <b>Nancy Carrasco (USA)</b> MCT8 as thyroid hormone exporter in thyroid cells <b>Caterina Di Cosmo (USA)</b> Pendrin and apical iodide transport <b>Peter Kopp (USA)</b> Role of CIC5 in the thyroid <b>Marie-France van den Hove (Belgium)</b>	<b>Monday 13 Sept.</b> 4:45 pm - 6:15 pm
<b>SY14</b>	<b>DEVELOPMENT AND APPLICATIONS OF NOVEL THYROID HORMONE ANALOGUES</b> Physiological and pharmacological actions of thyroid hormone analogues <b>Thomas Scanlan (USA)</b> Cardiac effects of thyronamines <b>Ricardo Zucchi (Italy)</b> Use of TR-beta selective agonists in metabolic syndrome <b>Miriam O. Ribeiro (Brazil)</b> Non-genomic action of thyroid hormone analogues <b>Paul Davis (USA)</b>	<b>Monday 13 Sept.</b> 4:45 pm - 6:15 pm

SY15	<p><b>ADVANCES IN SURGICAL THERAPY OF THYROID CANCER</b></p> <p>Minimizing surgical risks (nerve monitoring, calcium management)  <b>Paolo Miccoli</b> (Italy)</p> <p>New methods (robotics, minimally invasive surgery)  <b>Woong Youn Chung</b> (Korea)</p> <p>Controversy on central neck dissection  <b>Gerard Doherty</b> (USA)</p> <p>Re-operation – when and how ?  <b>David Steward</b> (USA)</p>	<p><b>Tuesday 14 Sept.</b>  11:30 am - 01:00 pm</p>
SY16	<p><b>IMMUNO MECHANISMS IN AUTOIMMUNE THYROID DISEASES (AITD): NEW DEVELOPMENTS AND FUTURE DIRECTIONS</b></p> <p>Central Tolerance and AITD: the role of AIRE  <b>Basil Rapoport</b> (USA)</p> <p>Chemokines and thyroid autoimmunity  <b>Sergio Lira</b> (USA)</p> <p>The role of dendritic cells in AITD  <b>Claudia Pellizas</b> (Argentina)</p> <p>Vitamin D and AITD  <b>Klaus Badenhoop</b> (Germany)</p>	<p><b>Tuesday 14 Sept.</b>  11:30 am - 01:00 pm</p>
SY17	<p><b>MOLECULAR MECHANISMS OF THYROID CANCER – TRANSLATIONAL</b></p> <p>Defining poorly differentiated thyroid cancer  <b>Fulvio Basolo</b> (Italy)</p> <p>PI3K pathway in cancer progression  <b>Matthew Ringel</b> (USA)</p> <p>Sodium/Iodide transporter (NIS) dysregulation  <b>Christine Spitzweg</b> (Germany)</p> <p>BRAF mutation  <b>Janete Cerutti</b> (Brazil)</p>	<p><b>Tuesday 14 Sept.</b>  11:30 am - 01:00 pm</p>
SY18	<p><b>PREGNANCY AND THYROID DISEASES</b></p> <p>T4 transport across the placenta  <b>Shiao Chan</b> (UK)</p> <p>Treatment of hypothyroidism in pregnancy  <b>Greg Brent</b> (USA)</p> <p>Treatment of hyperthyroidism in pregnancy  <b>Graciela Alcaraz</b> (Argentina)</p> <p>Outcome of the CATS study in pregnant women  <b>John Lazarus</b> (UK)</p>	<p><b>Wednesday 15 Sept.</b>  11:30 am - 01:00 pm</p>
SY19	<p><b>MOLECULAR EPIDEMIOLOGY OF THYROID CANCER</b></p> <p>Population studies of genetic risk for thyroid cancer  <b>Krystian Jazdzweski</b> (USA)</p> <p>Susceptibility to differentiated thyroid cancer  <b>Erich Sturgis</b> (USA)</p> <p>Molecular signature of radiation induced thyroid tumors  <b>Vladimir Saenko</b> (Japan)</p> <p>Molecular signature of spontaneous thyroid tumors  <b>Adel El-Naggar</b> (USA)</p>	<p><b>Wednesday 15 Sept.</b>  11:30 am - 01:00 pm</p>



<b>SY20</b>	<b>DEVELOPMENTAL ROLE OF DEIODINASES</b> Role of deiodinases in adipogenesis <b>Jessica Hall</b> (USA) Deiodinases & senses (vision & hearing) <b>Douglas Forrest</b> (USA) Thyroid hormone action in bone <b>Cecilia Gouveia</b> (Brazil) Deiodinases & bone development <b>Graham Williams</b> (UK)	<b>Wednesday 15 Sept.</b> 11:30 am - 01:00 pm
<b>SY21</b>	<b>ISSUES IN THE MANAGEMENT OF LOW-RISK THYROID CANCER</b> How to define low-risk patients for initial and long-term management ? <b>Ian Hay</b> (USA) Roles of surgery and RAI (emphasis on micro or minimally invasive FTC) <b>Paul Ladenson</b> (USA) Follow-up of the patients "less than total thyroidectomy-no radioactive iodine" <b>Koichi Ito</b> (Japan)	<b>Wednesday 15 Sept.</b> 4:45 pm - 6:15 pm
<b>SY22</b>	<b>GENETICS OF AUTOIMMUNE THYROID DISEASES (AITD)</b> Approaches to identifying AITD susceptibility genes <b>Simon Pearce</b> (UK) Ethnic differences in the genetics of AITD <b>Takashi Akamizu</b> (Japan) The role of detoxifying genes in AITD <b>Joao Romaldini</b> (Brazil) Polyglandular syndromes and AITD: Immunogenetic mechanisms <b>George Kahaly</b> (Germany)	<b>Wednesday 15 Sept.</b> 4:45 pm - 6:15 pm
<b>SY23</b>	<b>ROLE OF REACTIVE OXYGEN SPECIES IN THYROID CELL BIOLOGY</b> DUOX and its maturation factor <b>Helmut Grasberger</b> (USA) DUOX 1 and thyroid H <sub>2</sub> O <sub>2</sub> generation <b>Xavier De Deken</b> (Belgium) Role of DUOX 2 and other NOX expression in the thyroid <b>Corinne Dupuy</b> (France) Hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors <b>Knut Krohn</b> (Germany)	<b>Wednesday 15 Sept.</b> 4:45 pm - 6:15 pm
<b>SY24</b>	<b>THYROID HORMONE ACTION AND LIPID/ENERGY METABOLISM</b> The role of TR-alpha in the regulation of energy metabolism <b>Jens Mittag</b> (Sweden) Bile acids and thyroid hormone activation <b>Georg Brabant</b> (UK) Cellular aspects of thyroid hormone effects on energy expenditure <b>Brian Kim</b> (USA) Thyroid hormone action in states of insulin-resistance and steatosis <b>Mary Elizabeth Patti</b> (USA)	<b>Wednesday 15 Sept.</b> 4:45 pm - 6:15 pm

SY25	<p><b>METASTATIC AND RECURRENT THYROID CANCER MANAGEMENT</b></p> <p>Radioiodine therapy and dosimetry <b>Markus Luster</b> (Germany)</p> <p>New imaging methods <b>Sophie Leboulleux</b> (France)</p> <p>Palliative therapies <b>Johannes Smit</b> (The Netherlands)</p> <p>Targeting the TSH receptor <b>Marvin Gershengorn</b> (USA)</p>	<p><b>Thursday 16 Sept.</b> 09:30 am - 11:00 am</p>
SY26	<p><b>THYROID DISEASES AND THE METABOLIC SYNDROME</b></p> <p>Thyroid function and body weight <b>Elizabeth Pearce</b> (USA)</p> <p>Insulin resistance and the thyroid <b>Hugo Niepomnische</b> (Argentina)</p> <p>Thyroid function and blood pressure <b>Bjorn O. Asvold</b> (Norway)</p> <p>Thyroid function and lipid profile <b>Gabriella Brenta</b> (Argentina)</p>	<p><b>Thursday 16 Sept.</b> 09:30 am - 11:00 am</p>
SY27	<p><b>CLINICALLY RELEVANT ALTERATIONS IN NON-THYROIDAL DISEASES ?</b></p> <p>Consumptive hypothyroidism <b>Stephen Huang</b> (USA)</p> <p>Regulation of Deiodinase 3 expression in the stressed heart <b>Werner Simonides</b> (The Netherlands)</p> <p>The low T3 syndrome in cardiac patients and its treatment with T3 <b>Giorgio Iervasi</b> (Italy)</p> <p>Nonthyroidal illness: adaptation or maladaptation, and what to do about it? <b>Greet van Den Berghe</b> (Belgium)</p>	<p><b>Thursday 16 Sept.</b> 09:30 am - 11:00 am</p>
SY28	<p><b>THYROID DEVELOPMENT</b></p> <p>Using mice model of thyroid follicular cell development <b>Roberto di Lauro</b> (Italy)</p> <p>Thyroid gene expression during human fetal development <b>Michel Polak</b> (France)</p> <p>C cell development <b>Mikael Nilsson</b> (Sweden)</p> <p>Mendelian and non-Mendelian mechanisms of thyroid dysgenesis <b>Guy Van Vliet</b> (Canada)</p>	<p><b>Thursday 16 Sept.</b> 09:30 am - 11:00 am</p>

## CLOSING CEREMONY

	<p>Presentation of Young Investigator Awards, and invitation to the next International Thyroid Congress 2015.</p>	<p><b>Thursday 16 Sept.</b> 11:15 am - 12:00 pm</p>
--	---	---